INTRODUCTION
The livestock industry has known about the importance of trace elements for more than 100 yr, and has used estimations of requirements to formulate diets to maximize production. With the advent of "organic" minerals and, in recent years, concerns about environmental contamination and increasing feed costs, questions about the absorption and utilization of trace elements have surfaced. The source and quality of a trace element relative to its usefulness to the animal, without exogenous contaminants, are now important in ingredient sourcing. With concern about the contamination of many imported inorganic mineral sources, cost is not the only criterion used.
REASON FOR CHANGE
The storage of a mineral in the liver or bone does not indicate that a mineral is available to the animal for metabolic function. A good example is the work of Bobilya et al. (1994) , who used bone biopsies to show that the health of a pig, as indicated by a lack of growth, subsided because of deficiency even though the animal had 27 mg/kg of Zn remaining in the bone. This classic work reminds us that the measurement of a trace element in organs may indicate absorption, but not utilization, by the animal. Although measurement of tissue concentration progressed from the 1960s and 1970s, the use of enzyme activity became the clue to evaluating metabolic availability and status indicators. O'Dell (1997) provided the most accurate definition of bioavailability as "the proportion of the element consumed that is utilized for a biochemical or physiologic Transporters in the absorption and utilization of zinc and copper 1 function." Thus, the end of the 20th century saw the ranking of inorganic forms by biovailabilities based on enzyme activity, growth performance, nutrient balance, and hepatic storage. An example of using growth performance to compare Zn bioavailabilities would be the research of the NCR-42 committee (Hollis et al., 2005) , which compared Zn forms for their ability to stimulate growth when using pharmacological concentrations. Rincker et al. (2005) showed that the excretion pattern of nursery pigs fed ZnO and Zn-methionine differed when fed at pharmacological concentrations. Pigs fed 2,000 mg/kg of Zn from Zn-methionine excreted more urinary Zn, indicating greater absorption than those fed the same amount of Zn from ZnO, even though the concentration of Zn in the liver did not differ from feeding these 2 sources. It is also important to note that this work clearly shows that pigs must load their body with Zn for 10 to 14 d before fecal excretion of Zn is increased. Thus, the time in the loading period when a measurement for hepatic Zn concentration is made would give a very different result if one chose this outof-date method of measuring hepatic Zn to determine bioavailability. This is reiterated in the review by Hambridge (2003) when he noted that the assay of a trace mineral in plasma or serum is not a good biomarker for status for any trace element except Se. Plasma or serum mineral concentrations are often confounded because of increases or decreases in the concentration of many trace elements in the plasma, serum, and liver that occur during an acute-phase response, resulting in an aberrant indication of status.
Since the treatise of Hill and Spears (2000) on trace and ultratrace elements in swine, many new discoveries have been made on a more molecular level relative to the use of trace elements in the body. Eukaryotic cells, genetically altered mice (such as knockout mice), and inborn errors of metabolism in humans have provided scientists with new opportunities for the application of molecular techniques. This has led researchers to conclude that there are multiple levels of protein regulation, and they hypothesize that metal-responsive transcription factors exist (Rutherford and Bird, 2004) . Although many of these discoveries have yet to be made in mammals, even fewer have been made in nonrodent mammals such as livestock species.
Zn TRANSPORTERS
In a mini-review, Cousins et al. (2006) noted that 3 to 10% of the genes in the human genome code for proteins with Zn-binding domains. Thus, the body must maintain Zn homeostasis for health and longevity. It has been shown at the level of the organism that this occurs by controlled regulation of absorption from the intestine and loss from the endogenous secretions of the pancreas and intestines. At the cellular level, Zn concentrations are adjusted by uptake and secretion, by redistribution, and even by sequestration. Hence, the transportation of Zn is essential for life.
ZnT
In 1995, Palmiter and Findley identified the first Zn transporter gene, ZnT1. Before their discovery, Zn was thought to move in the body via an anionic or AA complex or chelate, or with transferrin receptors. The ZnT protein family has been referred to as part of the solute-linked carrier (SLC30) family. It is known for decreasing intracellular Zn via efflux from cells or influx into intracellular vesicles. Although the mechanism of these transporters is unknown, Chimienti et al. (2004) reported that a great deal of homology exists within the human ZnT proteins. This 10-member family has been found in mammalian cells, yeasts, and frog oocytes. The sequence of these family members differs in size, but all are believed to have 6 transmembrane domains, except ZnT5, which has 12. Four of these domains are thought to form a channel so Zn can be translocated. In addition, the sequence homology indicates the presence of both N and C termini on the cytoplasmic side of the membrane and an intracellular loop with several histidine residues to facilitate its role as the primary regulator of Zn removal by the cell.
Although most ZnT proteins are in intracellular compartments, such as the Golgi or endoplasmic reticulum, Cousins et al. (2006) reported that ZnT1 is located at the plasma membrane, ZnT2 is involved in vesicular localization of pancreatic acinar cells, and ZnT5 is present in the secretory vesicles of the pancreatic β cells and at the apical membranes of the enterocytes. The ZnT9 protein is found in the nucleus during mitosis. Using immunohistochemical analysis, Yu et al. (2007) reported that in the mouse, ZnT1 is expressed in the epithelium of several parts of the gastrointestinal tract (i.e., the esophagus, duodenum, and cecum), whereas ZnT4 is primarily found in the large intestine. The ZnT6 protein was detected in the stomach, jejunum, cecum, colon, and rectum. The ZnT7 protein has been found in all parts of the gastrointestinal tract, with the greatest expression in the small intestine (Yu et al., 2007) . Given the importance of maintaining the appropriate amounts of Zn for the growing embryo and fetus, it is not surprising that the ZnT proteins are found in the placenta. Helston et al. (2007) reported that the expression of ZnT in the mouse placenta is responsive to dietary Zn. Metallothionein (Mt), ZnT1, and ZnT4 transcript concentrations are reduced when dietary Zn concentrations are below or 3-fold above the adequate amount (Helston et al., 2007) . In the villous syncytiotrophoblast of humans, ZnT1 and ZnT5 were also detected (Helston et al., 2007) .
Zip
The Zip mammalian members of the SLC39 family, which are involved in Zn transport activity, are Zip1 to Zip8 and Zip14. Their role in Zn uptake is believed to be a facilitated process driven by concentration gradient and not requiring ATP. Although Zip proteins are specific for Zn, they can be inhibited by several other cations. Most Zip proteins are believed to have 8 transmembrane domains; their N and C termini are extracellular and have a long intracellular loop that contains many histidines. In contrast, Zip14 is believed to have an extracellular loop (Cousins et al., 2006) .
Most Zip proteins are thought to be located at the plasma membrane, but Zip7 is located at the Golgi apparatus. To serve their role, Zip proteins are able to change, depending on Zn availability and the physiological condition. The transport protein Zip4 will increase in the plasma membrane of enterocytes when Zn is restricted and will decrease its expression to basal conditions if Zn is refed (Cousins et al., 2006) . The Zip14 protein increases Zn uptake in the hepatocyte during an acute-phase response (Cousins et al., 2006) . Thus, the regulation of Zip genes by dietary Zn, and hence the presence of Zip proteins, may be important in managing Zn in livestock species, yet it appears that this family has not been investigated in farm species.
Regulation of Transporters and Mt
The ZnT protein, ZnT1, is regulated differently among tissues by metal-responsive transcription factor 1 and the abundance of mRNA when Zn is supplied in the diet at different concentrations. In our laboratory (Martinez, 2004) , we found that the expression of ZnT1 protein in the liver was greater in pigs fed 1,000 mg/ kg of Zn with or without phytase than in pigs fed 2,000 mg/kg of Zn with or without phytase. Interestingly, the response of Mt in the intestinal mucosa of these pigs did not follow this pattern. The Mt protein concentration was significantly greater in the mucosa of pigs fed 2,000 mg/kg of Zn plus phytase compared with 2,000 mg/kg of Zn as ZnO without phytase. However, this S-AA-rich protein in the mucosa was significantly greater in pigs fed the 2,000 mg/kg of dietary Zn than when pigs were fed 1,000 mg/kg of Zn plus phytase. This has led us to propose that both ZnT1 and Mt are involved in regulating Zn homeostasis in nursery pigs fed pharmacological amounts of Zn. In another study, when nursery pigs were fed 100, 1,000, or 4,000 mg/kg of Zn, the Mt protein in the mucosal cells of the duodenum was significantly greater in the pigs fed either 1,000 or 4,000 mg/kg of Zn than in those fed 100 mg/kg of Zn. The abundance of Mt did not differ between 1,000 and 4,000 mg/kg of Zn. However, further down the small intestine in the jejunum, where the total amount of Zn absorbed is greater but the amount per unit of intestinal surface area is less, pigs fed 4,000 mg/kg of Zn had significantly more Mt protein than those fed 1,000 or 100 mg/kg of Zn (Martinez et al., 2005) . Hypothetically, the Mt protein in the duodenum reduced the Zn available for absorption in the jejunum via intestinal cell sloughing, resulting in a different amount of Zn seen by the jejunum. With the loss of Zn bound to Mt in the jejunum, less Zn stimulated the production of ZnT1 because of the greater amount of Zn bound to Mt in the liver.
Cu TRANSPORTERS
Single-cell organisms, human metabolic disorders, and molecular techniques have helped to elucidate Cu metabolism in mammals. Individuals with Wilson's disease abnormally accumulate Cu in their body, whereas those with Menkes disease have an X-linked Cu mismanagement disorder, leading to deficiencies and accumulations of Cu in various organs because of a deficiency of the Cu transport protein (Hill et al., 1987; Cater and Mercer, 2005; Vonk et al., 2008) . Individuals with Menkes disease may have a lack of pigmentation of the hair and skin, growth retardation, neurological dysfunction, and connective tissue abnormalities (Cater and Mercer, 2005) . Patients with Wilson's disease can have liver dysfunction, neurological dysfunction, or both, or can die because of loss of red blood cell integrity (Hill et al., 1987) . The Bedlington terrier is also genetically predisposed to a metabolic Cu error. As a required nutrient, Cu presents problems to the body because it exists in 2 redox states and can change states by accepting or donating electrons. Thus, like Fe, it must be bound to a protein to prevent the production of free radicals through Fenton reactions. Most importantly, the amount of Cu in the body must be tightly regulated and the delivery to cells carefully managed. The absorption of Cu occurs primarily in the duodenum, when it is transferred across the brush border into the enterocytes (Cater and Mercer, 2005) . However, the uptake across the apical surface of these specialized cells of the intestinal mucosa is not understood. Two proteins that may be involved are 1) a high-affinity Cu transport protein (Ctr1), which is a ubiquitously expressed transmembrane protein, and 2) the divalent metal transporter protein (DMT1) in the brush border, also called nramp (Cater and Mercer, 2005) .
DMT1
The DMT1 is known to be involved in the cellular uptake of Cu , and Mn 2+ . However, it may not be involved in the regulation of Cu uptake when Cu is limited or when the other trace elements are absent (Cater and Mercer, 2005) .
Ctr1
The protein Ctr1 makes it possible for Cu to cross into a cell (Zhou and Gitschier, 1997) . This protein has 3 transmembrane regions that are rich in histidine and methionine for binding Cu. There is some evidence that this protein forms a channel through which Cu crosses. Therefore, Ctr1 becomes a point of regulation by internalizing into the plasma membrane and degrading in endosomal compartments when Cu is in excess. The
Transporters of zinc and copper Ctr1 gene is found in all tissues that have been examined, with the greatest amount found in the liver (Cater and Mercer, 2005) . This is consistent with the need for Cu by hepatic cells because of the elevated metabolic role of the liver. When Cu is delivered to the cell by Crtl, it is in the Cu 2+ state, and it is transferred by an unknown mechanism to chaperone proteins as Cu 1+ (Cater and Mercer, 2005) . As eloquently described by Field et al. (2002) , to provide Cu to metalloenzymes, "organisms have evolved with a family of intracellular Cu-binding proteins that help reserve a bioavailable pool of Cu for the metalloenzymes, escort the metal to appropriate targets, and directly transfer the Cu ion."
COX17
To date, 3 chaperone proteins have been identified, and the transfer of Cu to these small proteins may be a means of regulating where and how much Cu is located in various structures for the tasks at hand. The cytochrome c oxidase Cu chaperone (COX17) transports Cu to the mitochondria, where it transfers Cu to cytochrome c oxidase in the mitochondrial intermembrane space (Maxfield et al., 2004) . Whereas COX17 delivers Cu to the mitochondria, 2 other proteins (SCO1 and SCO2) may be involved in the incorporation of Cu into the cytochrome c oxidase molecule (Bertinato and L'Abbe, 2004) . The importance of Cu in the cytochrome c oxidase enzyme for efficient energy utilization should not be underestimated when one reviews the most efficient production of ATP within the cell.
CCS
A primarily cytoplasmic enzyme, superoxide dismutase (SOD), requires Cu and Zn to function, and Cu is delivered by the Cu chaperone protein (CCS). Because SOD is important in removing the superoxide radical, it is an essential antioxidant enzyme in the cytoplasm, but approximately 1 to 2% has also been found in the intermembrane space of mitochondria in eukaryotes (Field et al., 2002) . The CCS protein is necessary to convert apo-SOD to holo-SOD and has been found to be responsive to changes in Cu status. We recently found CCS in pigs supplemented with an organic form of Cu (G. M. Hill and J. E. Link, unpublished data). suggested that this 70-kDA protein could become a biomarker for assessing Cu status, because they observed a dose-dependent upregulation in CCS expression in the liver and red blood cells of Cu-deficient rats. This is in contrast to SOD activity in the liver, red blood cells, and brain, which did not distinguish when Cu status was changed as rats were fed normal, moderately Cu-deficient, or Cu-deficient diets. reported that when cell culture techniques were used, Cu was shown to regulate CCS expression by controlling degradation by the 26S proteosome. This may be one of the ways that mammals protect essential cells, such as in the heart, when the amount of Cu is limited in an organism.
For some time, we have known about the impact of high or pharmacological concentrations of dietary Zn on the Cu status of animals. In 1983, we reported that adding 5,000 mg/kg of Zn as ZnO to developing gilt and sow diets would result in Cu deficiency in the neonatal pig (Hill et al., 1983) . This same metabolic interaction has been used to control Cu uptake from the gastrointestinal tract in Wilson's disease patients. The increase in Mt in the intestine after feeding pharmacological concentrations of Zn results in increased losses of Cu as the mucosal cells of the gut are sloughed, which contain the Cu to which Mt prefers to bind (Hill and Spears, 2000) . Without a good biomarker for Cu status from tissue that is easy to obtain in the live animal, researchers have not been able to follow changes in status. However, CCS appears to have solved this problem. Iskandar et al. (2005) reported that CCS expression in the red blood cells was responsive to a mild Cu deficiency when ceruloplasmin and plasma Cu were not. In this same study, they found that Mt1, ZnT1, ZnT2, and ZnT4 were all increased significantly in the duodenum of rats fed 240 mg/kg of Zn compared with those fed 30, 60, or 120 mg/kg of Zn. As expected, Zip4 was increased in the duodenum of rats fed 30 and 60 mg/kg of Zn compared with those fed 120 and 240 mg/kg of Zn. Thus, these transporters for Zn and Cu may be useful in helping us understand the biological mechanisms involved in the feeding of pharmacological Zn, Cu, or both.
Atox1
Another Cu chaperone protein (Atox1) delivers Cu to ATP7A (Cu-transporting ATPase 1) and ATP7B (Cu-transporting ATPase 2) through direct interaction with these proteins. These 2 closely related P-type ATPases that deliver Cu to cuproenzymes normally are found in the trans-Golgi network, where Cu is incorporated into Cu enzymes such as lysyl oxidase, ceruloplasmin, and so forth (Cater and Mercer, 2005) . If Cu concentrations in the cell are increased, ATP7A moves to the plasma membrane to expel Cu, and ATP7B takes Cu to the vesicular compartments for storage. Thus, besides the role of Cu delivery to essential cuproenzymes, these ATPases help the cell to eliminate excess Cu or sequester Cu as a means of detoxification. The liver is the primary organ for Cu homeostasis. It serves as a storage organ for Cu and is involved in regulating the amount of Cu in the body by excreting Cu into the plasma as ceruloplasmin or in the bile in a form that cannot be reabsorbed. The metabolic error in Wilson's disease patients involves their inability to excrete the appropriate amount of Cu in bile because of an error in manufacturing the protein, ATP7B. Menkes disease patients have insufficient uptake and distribution of Cu because of the defective Menkes gene, ATP7A. The brain becomes Cu deficient because ATP7A is inadequate for the movement of Cu across the blood-brain barrier. Thus, Atox1 is the first connection from Ctr1 to move Cu to an ATPase (ATP7A or ATP7B) that will ultimately deliver it to the many essential enzymes that require Cu (Cater and Mercer. 2005) .
OTHER Cu AND Zn PROTEINS
Other proteins interact with Cu in meeting the needs of the animal or in reducing the risk from free or ionic Cu. In the Bedlington terrier, an autosomal recessive gene, MURR1 or COMMD1 (COOM domain-containing 1) has been shown to interact with ATP7B (Bertinato and L'Abbé, 2004) . This protein appears to have many roles in the body of mammals. However, its role in Cu metabolism is unknown, but affected Bedlington terriers accumulate Cu in the liver in a manner similar to patients with Wilson's disease (Bertinato and L'Abbé, 2004) . Although the homology of Mt has been preserved across a wide number of species and through evolutionary time (Hill and Spears, 2000) , the primary role of this low molecular weight protein with a high S content is unknown. Certainly, one of its roles is to serve as a depository for excess Cu, Zn, and other similar cations, and ultimately as a biological means of reducing the toxicity of these elements. It is possible that it not only prevents absorption of excess Cu and Zn, but also may be involved in holding these elements in the correct valance state or orientation for absorption.
Summary and Conclusions
With increasing feed costs, concerns about product quality, and the need to reduce the minerals entering the environment through excretion, we are challenged to find the correct dietary concentrations of Cu and Zn, as well as other required nutrients for the species, genetics, physiological state, and environment of our livestock. The molecular techniques of today and tomorrow are tools we must adopt to move forward to gain this information.
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